Taiwan · Delayed Price · Currency is TWD Concord Medical Statistics
Total Valuation
Concord Medical has a market cap or net worth of TWD 1.02 billion. The enterprise value is 1.00 billion.
| Market Cap | 1.02B |
| Enterprise Value | 1.00B |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | Apr 10, 2026 |
Share Statistics
Concord Medical has 33.33 million shares outstanding. The number of shares has increased by 0.84% in one year.
| Current Share Class | 33.33M |
| Shares Outstanding | 33.33M |
| Shares Change (YoY) | +0.84% |
| Shares Change (QoQ) | +0.41% |
| Owned by Insiders (%) | 12.83% |
| Owned by Institutions (%) | n/a |
| Float | 6.34M |
Valuation Ratios
The trailing PE ratio is 12.01.
| PE Ratio | 12.01 |
| Forward PE | n/a |
| PS Ratio | 0.98 |
| PB Ratio | 1.36 |
| P/TBV Ratio | 1.45 |
| P/FCF Ratio | 7.93 |
| P/OCF Ratio | 7.77 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.70, with an EV/FCF ratio of 7.78.
| EV / Earnings | 11.66 |
| EV / Sales | 0.96 |
| EV / EBITDA | 6.70 |
| EV / EBIT | 14.50 |
| EV / FCF | 7.78 |
Financial Position
The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.24.
| Current Ratio | 1.66 |
| Quick Ratio | 1.59 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | 1.21 |
| Debt / FCF | 1.40 |
| Interest Coverage | 17.11 |
Financial Efficiency
Return on equity (ROE) is 12.00% and return on invested capital (ROIC) is 8.37%.
| Return on Equity (ROE) | 12.00% |
| Return on Assets (ROA) | 3.58% |
| Return on Invested Capital (ROIC) | 8.37% |
| Return on Capital Employed (ROCE) | 7.84% |
| Weighted Average Cost of Capital (WACC) | 5.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.86 |
| Inventory Turnover | 82.46 |
Taxes
In the past 12 months, Concord Medical has paid 14.49 million in taxes.
| Income Tax | 14.49M |
| Effective Tax Rate | 14.35% |
Stock Price Statistics
The stock price has increased by +17.94% in the last 52 weeks. The beta is 0.30, so Concord Medical's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +17.94% |
| 50-Day Moving Average | 31.10 |
| 200-Day Moving Average | 28.76 |
| Relative Strength Index (RSI) | 46.82 |
| Average Volume (20 Days) | 4,601 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Concord Medical had revenue of TWD 1.04 billion and earned 85.79 million in profits. Earnings per share was 2.55.
| Revenue | 1.04B |
| Gross Profit | 147.33M |
| Operating Income | 68.99M |
| Pretax Income | 101.00M |
| Net Income | 85.79M |
| EBITDA | 122.02M |
| EBIT | 68.99M |
| Earnings Per Share (EPS) | 2.55 |
Balance Sheet
The company has 225.93 million in cash and 179.94 million in debt, with a net cash position of 45.99 million or 1.38 per share.
| Cash & Cash Equivalents | 225.93M |
| Total Debt | 179.94M |
| Net Cash | 45.99M |
| Net Cash Per Share | 1.38 |
| Equity (Book Value) | 751.62M |
| Book Value Per Share | 21.74 |
| Working Capital | 222.52M |
Cash Flow
In the last 12 months, operating cash flow was 131.26 million and capital expenditures -2.62 million, giving a free cash flow of 128.64 million.
| Operating Cash Flow | 131.26M |
| Capital Expenditures | -2.62M |
| Depreciation & Amortization | 53.03M |
| Net Borrowing | -79.29M |
| Free Cash Flow | 128.64M |
| FCF Per Share | 3.86 |
Margins
Gross margin is 14.19%, with operating and profit margins of 6.64% and 8.26%.
| Gross Margin | 14.19% |
| Operating Margin | 6.64% |
| Pretax Margin | 9.73% |
| Profit Margin | 8.26% |
| EBITDA Margin | 11.75% |
| EBIT Margin | 6.64% |
| FCF Margin | 12.39% |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 4.96%.
| Dividend Per Share | 1.50 |
| Dividend Yield | 4.96% |
| Dividend Growth (YoY) | 36.36% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 58.28% |
| Buyback Yield | -0.84% |
| Shareholder Yield | 3.91% |
| Earnings Yield | 8.41% |
| FCF Yield | 12.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |